Price chart (1D to 10Y)
Licensed market data — shown to members, not published to the open web.
Valuation vs Instaport thresholds (P/E, PEG, P/FCF, P/S)
Licensed market data — shown to members, not published to the open web.
Profile
From SEC filingsCompany description
32, 35 - 46, 57 - 59, 63 - 70, 180 - 182, 221 - 223, 255 - 268 C. Organisational structure 247, 288 - 295 D. Property, plant and equipment 89, 181, 192 - 193 4A Unresolved staff comments Not applicable 5 Operating and Financial Review and Prospects A. Operating results 9 - 10, 71 - 96, 228, 235 - 238, 241 - 242 B. Liquidity and capital resources 88 - 93, 95, 96, 199, 201 - 202, 215, 227 - 244 C. Research and development, patents and licences, etc. 12 - 32, 255 - 259 D. Trend information 71 - 96 E. Critical accounting estimates Not applicable 6 A. Directors, Senior Managers and Employees A. Directors and senior management 98 - 103 B. Compensation 127 - 155, 245 - 246 C. Board practices 6 - 7, 98 - 101, 106, 120 - 127, 148, 280 - 281, D. Employees 185, 203 - 211, 254 E. Share ownership 134, 136, 140, 141, 151 - 152, 245 - 246 F. Disclosure of a registrant’s action to recover erroneously awarded compensation Not applicable 7 Major Shareholders and Related Party Transactions A. Major shareholders 156, 269 - 271 B. Related party transactions 220 C. Interests of experts and counsel Not applicable 8 Financial Information A. Consolidated Financial Statements and Other Financial Information 158 - 252, 271 B. Significant Changes 248 - 251 9 The Offer and Listing A. Offer and listing details 270 B. Plan of distribution Not applicable C. Markets 269 - 270 D. Selling shareholders Not applicable E. Dilution Not applicable GSK 2025 Annual Report on Form 20-F Form 20-F Cross Reference Guide continued F.
Read the full filing description · filed 6 Mar 2026
At a glance
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
Source: SEC filings. Information and analytics, not investment advice.